Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity

Next Previous
Trial Profile

Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use

Most Recent Events

  • 02 May 2016 Primary endpoint has not been met, (Body Weight (kg)), according to results published.
  • 02 May 2016 Results (n=10) assessing the effects of exenatide on body weight were published in the Obesity (Silver Spring, Md.).
  • 02 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top